SELECTBIO - Stem Cells in Drug Discovery Tox & Organoids 2019 Biographies

Home

Agenda

Keynote Speakers

Registration

Exhibition

Venue

Training Courses

Co-Located Conferences

Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer

Monday, 14 October 2019 at 14:30

Add to Calendar ▼2019-10-14 14:30:002019-10-14 15:30:00Europe/LondonOrganoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic CancerStem Cells in Drug Discovery Tox and Organoids 2019 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com

New approaches to prioritize treatment strategies are urgently needed to improve survival and quality of life for pancreatic cancer patients. Combined genomic, transcriptomic, and therapeutic profiling of patient-derived organoids can identify molecular and functional subtypes of pancreatic cancer, predict therapeutic responses and facilitate precision medicine for pancreatic cancer patients.

Hervé Tiriac, Assistant Researcher, University of California-San Diego

Dr. Tiriac received his Ph.D. from UC San Diego studying pre-mRNA splicing and transcription with Dr. Tracy Johnson. Herve’s research focuses on developing systems for precision medicine that may be utilized in the fight against pancreatic cancer. Herve did his postdoctoral fellowship with David Tuveson at Cold Spring Harbor Laboratory where he collaborated with Hans Clevers to establish protocols for PDAC organoid generation and testing.